American Journal of Kidney Diseases
Volume 51, Issue 4 , Pages 563-572 , April 2008

Socioeconomic Status and the Incidence of ESRD

  • Michael M. Ward, MD, MPH

      Affiliations

    • Corresponding Author InformationAddress correspondence to Michael Ward, MD, MPH, NIAMS/NIH, Bldg 10 CRC, Rm 4-1339, 10 Center Dr, MSC 1468, Bethesda, MD 20892.

Received 20 June 2007 ,Accepted 27 November 2007.

References 

  1. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  3. Whittle JC, Whelton PK, Seidler AJ, Klag MJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease?. Arch Intern Med. 1991;151:1359–1364
  4. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ. The excess incidence of diabetic end-stage renal disease among blacks (A population-based study of potential explanatory factors). JAMA. 1992;268:3079–3084
  5. Cass A, Cunningham J, Wang Z, Hoy W. Social disadvantage and variation in the incidence of end-stage renal disease in Australia capital cities. Aust N Z J Public Health. 2001;25:322–326
  6. Maheswaran R, Payne N, Meechan D, et al. Socioeconomic deprivation, travel distance, and renal replacement therapy in the Trent Region, United Kingdom 2000: An ecological study. J Epidemiol Community Health. 2003;57:523–524
  7. Li S, McAlpine DD, Liu J, Li S, Collins AJ. Differences between blacks and whites in the incidence of end-stage renal disease and associated risk factors. Adv Ren Replace Ther. 2004;11:5–13
  8. Young EW, Mauger EA, Jiang K-H, Port FK, Wolfe RA. Socioeconomic status and end-stage renal disease in the United States. Kidney Int. 1994;45:907–911
  9. Byrne C, Nedelman J, Luke RG. Race, socioeconomic status, and the development of end-stage renal disease. Am J Kidney Dis. 1994;23:16–22
  10. Perneger TV, Whelton PK, Klag MJ. Race and end-stage renal disease (Socioeconomic status and access to health care as mediating factors). Arch Intern Med. 1995;155:1201–1208
  11. Klag MJ, Whelton PK, Randall BL, Meaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men (16-Year MRFIT findings). JAMA. 1997;277:1293–1298
  12. Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703–1720
  13. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–389
  14. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA. 2003;290:2159–2167
  15. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  16. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117
  17. Hellman R, Regan J, Rosen H. Effect of intensive treatment of diabetes of the risk of death or renal failure in NIDDM and IDDM. Diabetes Care. 1997;20:258–264
  18. Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Diabetes Care. 2000;23:1478–1485
  19. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis (Controlled trial of prednisone and cytotoxic drugs). N Engl J Med. 1986;314:614–619
  20. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248–257
  21. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971–980
  22. Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at high risk for end-stage renal disease. J Am Soc Nephrol. 1997;8:1560–1567
  23. Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003;63:678–685
  24. Paterson AD, Magistroni R, He N, et al. Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2005;16:755–762
  25. US Renal Data System (USRDS 2005 Annual Data Report). Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005;
  26. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12:703–711
  27. Diez Roux AV, Kiefe CI, Jacobs DR, et al. Area characteristics and individual-level socioeconomic position indicators in three population-based epidemiologic studies. Ann Epidemiol. 2001;11:395–405
  28. Census 2000 Summary File 3—United States/prepared by the US Census Bureau. http://factfinder.census.gov2002;Accessed December 22, 2005
  29. Merkin SS, Coresh J, Diez Roux AV, Taylor HA, Powe NR. Area socioeconomic status and progressive CKD: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2005;46:203–213
  30. Shoham DA, Vupputuri S, Diez Roux AV, et al. Kidney disease in life-course socioeconomic context: The Atherosclerotic Risk in Communities (ARIC) Study. Am J Kidney Dis. 2007;49:217–226
  31. Beach MC, Hill-Briggs F, Cooper LA. Racial and ethnic differences in receipt and use of health information in encounters between patients and physicians. Med Care. 2006;44:97–99
  32. Lloyd CE, Wing RR, Orchard TJ, Becker DJ. Psychosocial correlates of glycemic control: The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. Diabetes Res Clin Pract. 1993;21:187–195
  33. Bihan H, Laurent S, Sass C, et al. Association among individual deprivation, glycemic control, and diabetes complications: The EPICES score. Diabetes Care. 2005;28:2680–2685
  34. Kuo Y-F, Ray LA, Raji MA, Espino DV, Markides KS, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period. Diabetes Care. 2003;26:3054–3060
  35. Bell RA, Camacho F, Goonan K, et al. Quality of diabetes care among low-income patients in North Carolina. Am J Prev Med. 2001;21:124–131
  36. Chaturvedi N, Stephenson JM, Fuller JH. The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM Complications study. Diabetes Care. 1996;19:423–430
  37. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287:2519–2527
  38. Goldman DP, Smith JP. Can patient self-management help explain the SES health gradient?. Proc Natl Acad Sci U S A. 2002;99:10929–10934
  39. Ward MM. Medical insurance, socioeconomic status, and age at onset of endstage renal disease in patients with lupus nephritis. J Rheumatol. 2007;34:2024–2027
  40. Vermeire E, Wens J, van Royen P, Biot Y, Hearnshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev CD003638. 2005;
  41. Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. Arthritis Care Res. 2000;13:406–408
  42. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32:913–919
  43. Thom DH, Ribisl KM, Stewart AL, Luke DA. Further validation and reliability testing of the Trust in Physician Scale (The Stanford Trust Study Physicians). Med Care. 1999;37:510–517
  44. Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. JAMA. 2002;288:475–482
  45. Singh-Manoux A, Marmot M. Role of socialization in explaining social inequalities in health. Soc Sci Med. 2005;60:2129–2133
  46. Helman CG. Culture, Health and Illness. New York, NY: Arnold; 2001;
  47. Whitfield KE, Weidner G, Clark R, Anderson NB. Sociodemographic diversity and behavioral medicine. J Consult Clin Psychol. 2002;70:463–481
  48. Dunlop DD, Manheim LM, Song J, Chang RW. Gender and ethnic/racial disparities in health care utilization among older adults. J Gerontol B Psychol Sci Soc Sci. 2002;57(suppl):S221–S233
  49. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates using hospitalization data. Arthritis Rheum. 2007;56:2092–2093
  50. Geronimus AT, Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: Evidence from national samples. Am J Epidemiol. 1998;148:475–486
  51. Kreiger N, Chen JT, Waterman PD, Soobader M-J, Subramanian SV, Carson R. Choosing area based socioeconomic measures to monitor social inequalities in low birth weight and childhood lead poisoning: The Public Health Disparities Geocoding Project (US). J Epidemiol Community Health. 2003;57:186–199
  52. Smith GD, Neaton JD, Wentworth D, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: I (White men). Am J Public Health. 1996;86:486–496
  53. Smith GD, Neaton JD, Wentworth D, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: II (Black men). Am J Public Health. 1996;86:497–504
  54. Banks J, Marmot M, Oldfield Z, Smith JP. Disease and disadvantage in the United States and in England. JAMA. 2006;295:2037–2045
  55. Phelan JC, Link BG. Controlling disease and creating disparities: A fundamental cause perspective. J Gerontol B Psychol Sci Soc Sci. 2005;60B:27–33

 Originally published online as doi:10.1053/j.ajkd.2007.11.023 on February 7, 2008.

PII: S0272-6386(07)01609-5

doi: 10.1053/j.ajkd.2007.11.023

American Journal of Kidney Diseases
Volume 51, Issue 4 , Pages 563-572 , April 2008

Article Tools

* Image Usage & Resolution